EXCLUSIVE: Lisata Therapeutics Tells Benzinga Co. And Haystack Oncology Initiate Research Collaboration To Use The Haystack MRD Technology To Evaluate Efficacy Of Pancreatic Cancer Therapy
Portfolio Pulse from Benzinga Newsdesk
Lisata Therapeutics and Haystack Oncology have initiated a research collaboration to use Haystack's MRD technology to evaluate the efficacy of a pancreatic cancer therapy.
July 18, 2024 | 11:30 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Lisata Therapeutics has entered into a research collaboration with Haystack Oncology to use Haystack's MRD technology for evaluating the efficacy of a pancreatic cancer therapy.
The collaboration with Haystack Oncology could potentially lead to advancements in pancreatic cancer treatment, which may positively impact Lisata Therapeutics' stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEUTRAL IMPACT
Although not directly mentioned, Quest Diagnostics (DGX) could be indirectly impacted as it operates in the diagnostics space and may benefit from advancements in MRD technology.
Quest Diagnostics operates in the diagnostics space and could see indirect benefits from advancements in MRD technology, but the impact is not immediate or direct.
CONFIDENCE 60
IMPORTANCE 40
RELEVANCE 20